PL2119703T3 - Nowe pochodne indolu o aktywności hamującej kinazę-ßIκB - Google Patents

Nowe pochodne indolu o aktywności hamującej kinazę-ßIκB

Info

Publication number
PL2119703T3
PL2119703T3 PL08703206T PL08703206T PL2119703T3 PL 2119703 T3 PL2119703 T3 PL 2119703T3 PL 08703206 T PL08703206 T PL 08703206T PL 08703206 T PL08703206 T PL 08703206T PL 2119703 T3 PL2119703 T3 PL 2119703T3
Authority
PL
Poland
Prior art keywords
kinase
inhibitory activity
indole derivative
novel indole
novel
Prior art date
Application number
PL08703206T
Other languages
English (en)
Inventor
Hiroshi Enomoto
Kenji Kawashima
Kazuhiro Kudou
Minoru Yamamoto
Masaaki Murai
Takaaki Inaba
Noriko Ishizaka
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of PL2119703T3 publication Critical patent/PL2119703T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
PL08703206T 2007-01-15 2008-01-15 Nowe pochodne indolu o aktywności hamującej kinazę-ßIκB PL2119703T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007005554 2007-01-15
PCT/JP2008/050342 WO2008087933A1 (ja) 2007-01-15 2008-01-15 ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
EP08703206A EP2119703B1 (en) 2007-01-15 2008-01-15 Novel indole derivative having inhibitory activity on i b kinase

Publications (1)

Publication Number Publication Date
PL2119703T3 true PL2119703T3 (pl) 2013-04-30

Family

ID=39635937

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08703206T PL2119703T3 (pl) 2007-01-15 2008-01-15 Nowe pochodne indolu o aktywności hamującej kinazę-ßIκB

Country Status (11)

Country Link
US (1) US8193237B2 (pl)
EP (1) EP2119703B1 (pl)
JP (1) JP5070067B2 (pl)
KR (1) KR20090109551A (pl)
CN (1) CN101583598B (pl)
CA (1) CA2674865A1 (pl)
DK (1) DK2119703T3 (pl)
ES (1) ES2397292T3 (pl)
PL (1) PL2119703T3 (pl)
RU (1) RU2470918C2 (pl)
WO (1) WO2008087933A1 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2119703B1 (en) 2007-01-15 2012-12-12 Santen Pharmaceutical Co., Ltd Novel indole derivative having inhibitory activity on i b kinase
WO2010007972A1 (ja) * 2008-07-14 2010-01-21 参天製薬株式会社 カルバモイル基、ウレイド基及び置換オキシ基を有する新規インドール誘導体
WO2010024226A1 (ja) * 2008-08-25 2010-03-04 参天製薬株式会社 ウレイド基、アミノカルボニル基及び置換フェニル基を置換基として有するピロール誘導体を有効成分として含有する骨・関節疾患の予防又は治療剤
JP5492496B2 (ja) * 2008-08-25 2014-05-14 参天製薬株式会社 ウレイド基、アミノカルボニル基及び置換基を有してもよい二環式基を置換基として有する新規ピロール誘導体
CN102596879B (zh) * 2009-08-04 2015-01-28 奇斯药制品公司 制备1-(2-卤代联苯-4-基)-环丙烷羧酸的衍生物的方法
TWI562977B (en) * 2010-11-05 2016-12-21 Bayer Ip Gmbh Process for the preparation of substituted n-(benzyl)cyclopropanamines by imine hydrogenation
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
TWI634111B (zh) 2013-03-15 2018-09-01 普雷辛肯公司 雜環化合物及其用途
US9598446B2 (en) 2014-02-25 2017-03-21 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of complement mediated disorders
EA038607B1 (ru) * 2014-09-05 2021-09-22 Ачиллион Фармасьютикалс, Инк. Арильные, гетероарильные и гетероциклические соединения для лечения опосредованных комплементом расстройств
JP2018521021A (ja) 2015-06-11 2018-08-02 バジリア・ファルマスーチカ・インターナショナル・アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ａｇ 排出ポンプ阻害剤及びその治療的使用
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US10000516B2 (en) 2015-08-26 2018-06-19 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
ES2933513T3 (es) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Compuestos macrocíclicos para el tratamiento de trastornos médicos
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN111163767A (zh) 2017-08-02 2020-05-15 艾其林医药公司 治疗阵发性睡眠性血红蛋白尿症的治疗方案
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
US11021427B2 (en) 2018-04-19 2021-06-01 The Scripps Research Institute Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
BR112021005506A2 (pt) 2018-09-25 2021-06-15 Achillion Pharmaceuticals, Inc. formas mórficas de inibidores de fator complementar d
EP4267559A1 (en) * 2020-12-22 2023-11-01 Gilead Sciences, Inc. Substituted indole compounds
MX2023012110A (es) 2021-04-16 2023-10-24 Gilead Sciences Inc Compuestos de tienopirrol.
TWI849499B (zh) 2021-09-10 2024-07-21 美商基利科學股份有限公司 噻吩并吡咯化合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1079798C (zh) 1994-12-23 2002-02-27 拜尔公司 3－芳基－季酮酸衍生物、其生产和作为杀虫剂的应用和中间体
WO1996020191A1 (fr) 1994-12-28 1996-07-04 Sankyo Company, Limited Derives d'indole
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US7125906B2 (en) * 2002-04-03 2006-10-24 Astrazeneca Ab Indole derivatives having anti-angiogenetic activity
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
JP2005536518A (ja) 2002-07-19 2005-12-02 ファルマシア コーポレイション 炎症治療のための置換チオフェンカルボキサミド化合物
EP1569924A4 (en) * 2002-12-06 2007-02-21 Smithkline Beecham Corp NF-KB FACTOR INHIBITORS
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
KR20060088102A (ko) * 2003-09-04 2006-08-03 아벤티스 파마슈티칼스 인크. 폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ)의 억제제로서의치환된 인돌
US20070275962A1 (en) * 2003-09-10 2007-11-29 Gpc Biotech Ag Heterobicyclic Compounds as Pharmaceutically Active Agents
AP2006003637A0 (en) * 2003-11-06 2006-06-30 Celgene Corp Methods and compositions using thalidomide for thetreatment and management of cancers and other diseases
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
JP2007529426A (ja) * 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
JP2007277093A (ja) 2004-06-21 2007-10-25 Astellas Pharma Inc 三環系化合物
WO2006036031A1 (ja) 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited 縮合フラン誘導体およびその用途
US20080305516A1 (en) * 2004-11-30 2008-12-11 Kristian Kjaergaard Method of Producing Antibodies
JP2008546840A (ja) 2005-06-28 2008-12-25 メルク エンド カムパニー インコーポレーテッド 非ヌクレオシド逆転写酵素阻害剤
US20080293802A1 (en) 2005-12-16 2008-11-27 Smithline Beecham Corporation Chemical Compounds
EP2119703B1 (en) 2007-01-15 2012-12-12 Santen Pharmaceutical Co., Ltd Novel indole derivative having inhibitory activity on i b kinase
WO2010007972A1 (ja) 2008-07-14 2010-01-21 参天製薬株式会社 カルバモイル基、ウレイド基及び置換オキシ基を有する新規インドール誘導体

Also Published As

Publication number Publication date
US8193237B2 (en) 2012-06-05
JP5070067B2 (ja) 2012-11-07
EP2119703A1 (en) 2009-11-18
CN101583598A (zh) 2009-11-18
RU2470918C2 (ru) 2012-12-27
CN101583598B (zh) 2012-09-12
EP2119703B1 (en) 2012-12-12
ES2397292T3 (es) 2013-03-06
DK2119703T3 (da) 2013-01-14
WO2008087933A1 (ja) 2008-07-24
CA2674865A1 (en) 2008-07-24
RU2009131031A (ru) 2011-02-27
EP2119703A4 (en) 2010-08-25
JP2008195711A (ja) 2008-08-28
KR20090109551A (ko) 2009-10-20
US20100041628A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
EP2119703A4 (en) NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE
IL186644A0 (en) Substituted indole compounds having nos inhibitory activity
ZA201005210B (en) Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
SI2201012T1 (sl) Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
EP2172453A4 (en) COMPOUND HAVING 11 ß-HSD1 INHIBITION ACTIVITY
LT2754660T (lt) Piridazinono dariniai
IL205142A0 (en) Pyridazinone derivatives as parp inhibitors
ZA200908298B (en) Bicycloaniline derivative
EP2226315A4 (en) 2-AMINOQUINAZOLINE DERIVATIVE
EP2213673A4 (en) PYRIDONE-SUBSTITUTED DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE
ZA200909054B (en) Pyridazinone Derivatives
EP2208728A4 (en) HETEROCYCLIC DERIVATIVE DERIVATIVE DERIVATIVE TO 11 -? - HYDROXYSTEROIDDEHYDROGENASE TYPE I
HK1144196A1 (en) 4-pyrimidinesulfamide derivative 4-
EP2141148A4 (en) INDOLE DERIVATIVE HAVING CPLA <SB> 2 </ SB> INHIBITING ACTIVITY, USE THEREOF, AND METHOD FOR PRODUCTION THEREOF
EP2105435A4 (en) Hydrazone derivatives
IL206402A0 (en) Bicyclic heterocyclic derivative
EP2228376A4 (en) PYRIPYROPEN DERIVATIVE WITH ACAT2-HEMMENDER EFFECT
ZA200905265B (en) Indole derivatives
EP2163554A4 (en) PYRIMIDODIAZEPINONE DERIVATIVE
HK1192881A1 (zh) 全氫喹喔琳衍生物
EP2157084A4 (en) 5-phenyl-3-pyridazinone derivative
EP2017279A4 (en) NEW AMINO-PYRIDINE DERIVATIVE WITH AURORA A SELECTIVE HEMORATIVE EFFECT
EP2228362A4 (en) 4-HYDROXYPHENYLALKYLAMINE DERIVATIVE
EP2130829A4 (en) NEW HYDROXYINDOLE DERIVATIVE
AU2007902013A0 (en) Inhibitory compounds